Here are the top 5 articles detailing the advancements in hematologic oncology from 2025. BTK inhibitors have revolutionized treatment for hematologic malignancies, butacquired BTK mutations often ...
Kura Oncology, Inc. (NASDAQ:KURA) is one of the stocks Jim Cramer offered insights on. When a caller highlighted the ...
Abstract: Most of the current research on dynamic multiobjective optimization problems (DMOPs) assumes that environmental changes can be detectable. However, undetectable changes are frequently ...
Menin inhibitors target the interaction between menin and the KMT2A complex, offering a breakthrough in treating acute ...
The most-read coverage of the latest updates in acute myeloid leukemia (AML) for 2025 focused on the evolution of targeted ...
The American Society of Hematology/ASH 2025 meeting included AML results from AAML1831, MyeChild01, BIG-1, and PALG-AML1/2016 studies.
While patients with acute myeloid leukemia (AML) are routinely treated with chemotherapy and other cell-killing therapies, existing options do not lead to favorable clinical outcomes in all patients.
This study retrospectively analyzed ten pediatric patients with HOX-driven AML who received revumenib maintenance after HSCT at a single-center. The median age was 10 years (range: 1-18). 80% (8/10) ...
The final, formatted version of the article will be published soon. Objective:This study aimed to characterize TET2 mutations in CN-AML, assess their clinical features, and evaluate the prognostic ...
Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Revuforj ® (revumenib) was named Best New Drug at the ...
KOMZIFTI (ziftomenib), the first and only once-daily oral menin inhibitor for adult patients with R/R AML with a susceptible NPM1 mutation who have no satisfactory alternative treatment options, has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback